In this third up date of the Cochrane review , there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6 , B9 or B12 given alone or in combination comparing with placebo on myocardial infa rct ion , death from any cause or adverse events .
BACKGROUND Cardiovascular disease , which includes coronary artery disease , stroke and peripheral vascular disease , is a leading cause of death worldwide .
Homocysteine is an amino acid with biological functions in methionine metabolism .
A postulated risk factor for cardiovascular disease is an elevated circulating total homocysteine level .
The impact of homocysteine-lowering interventions , given to patients in the form of vitamins B6 , B9 or B12 supplements , on cardiovascular events has been investigated .
This is an up date of a review previously published in 2009 , 2013 , and 2015 .
OBJECTIVES To determine whether homocysteine-lowering interventions , provided to patients with and without pre-existing cardiovascular disease are effective in preventing cardiovascular events , as well as reducing all-cause mortality , and to evaluate their safety .
Effect of B-vitamins and n-3 PUFA supplementation for 5 years on blood pressure in patients with CVD.
Certain epidemiological and experimental studies suggest that n-3 fatty acids and folate can reduce blood pressure ( BP ) . We investigated the effect of a daily supplementation with dietary doses of B-vitamins or n-3 fatty acids for 5 years on BP in patients with a history of CVD who participated in the Supplémentation en Folates et Omega-3 trial . The patients ( n 2501 ; 1987 men and 514 women ) were r and omly assigned in a 2 × 2 factorial design to one of four groups : B-vitamins ( 5-methyl-THF ( 560 μg ) ; vitamin B₆ ( 3 mg ) and vitamin B₁₂ ( 20 μg ) ) and a placebo capsule for n-3 fatty acids ; n-3 fatty acids ( 600 mg of EPA and DHA at a ratio of 2:1 ) and a placebo capsule for B-vitamins ; both B-vitamins and n-3 fatty acids ; or placebo capsules for both treatments . The patients took two capsules daily in a double-blind manner for a median duration of 4·7 years . At baseline and annual examination for 5 years , the patients underwent a clinical examination where BP and clinical and biological parameters were assessed . No effect of supplementation with either n-3 PUFA or B-vitamins  on BP was observed in crude and adjusted multivariate models . Change in BP was not associated with change in homocysteine . In conclusion , the present results do not support the routine use of dietary supplements containing B-vitamins , or of n-3 fatty acids , to reduce BP in people with prior CVD
In this third up date of the Cochrane review , there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6 , B9 or B12 given alone or in combination comparing with placebo on myocardial infa rct ion , death from any cause or adverse events .
BACKGROUND Cardiovascular disease , which includes coronary artery disease , stroke and peripheral vascular disease , is a leading cause of death worldwide .
Homocysteine is an amino acid with biological functions in methionine metabolism .
A postulated risk factor for cardiovascular disease is an elevated circulating total homocysteine level .
The impact of homocysteine-lowering interventions , given to patients in the form of vitamins B6 , B9 or B12 supplements , on cardiovascular events has been investigated .
This is an up date of a review previously published in 2009 , 2013 , and 2015 .
OBJECTIVES To determine whether homocysteine-lowering interventions , provided to patients with and without pre-existing cardiovascular disease are effective in preventing cardiovascular events , as well as reducing all-cause mortality , and to evaluate their safety .